These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro. Nobuhara CK; DeVos SL; Commins C; Wegmann S; Moore BD; Roe AD; Costantino I; Frosch MP; Pitstick R; Carlson GA; Hock C; Nitsch RM; Montrasio F; Grimm J; Cheung AE; Dunah AW; Wittmann M; Bussiere T; Weinreb PH; Hyman BT; Takeda S Am J Pathol; 2017 Jun; 187(6):1399-1412. PubMed ID: 28408124 [TBL] [Abstract][Full Text] [Related]
25. Active full-length DNA Aβ Rosenberg RN; Fu M; Lambracht-Washington D Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039 [TBL] [Abstract][Full Text] [Related]
26. Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. Bolós M; Llorens-Martín M; Jurado-Arjona J; Hernández F; Rábano A; Avila J J Alzheimers Dis; 2016; 50(1):77-87. PubMed ID: 26638867 [TBL] [Abstract][Full Text] [Related]
27. Tau passive immunization inhibits not only tau but also Aβ pathology. Dai CL; Tung YC; Liu F; Gong CX; Iqbal K Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379 [TBL] [Abstract][Full Text] [Related]
28. Intersection of pathological tau and microglia at the synapse. Vogels T; Murgoci AN; Hromádka T Acta Neuropathol Commun; 2019 Jul; 7(1):109. PubMed ID: 31277708 [TBL] [Abstract][Full Text] [Related]
29. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. Congdon EE; Gu J; Sait HB; Sigurdsson EM J Biol Chem; 2013 Dec; 288(49):35452-65. PubMed ID: 24163366 [TBL] [Abstract][Full Text] [Related]
30. Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser van Ameijde J; Crespo R; Janson R; Juraszek J; Siregar B; Verveen H; Sprengers I; Nahar T; Hoozemans JJ; Steinbacher S; Willems R; Delbroek L; Borgers M; Dockx K; Van Kolen K; Mercken M; Pascual G; Koudstaal W; Apetri A Acta Neuropathol Commun; 2018 Jul; 6(1):59. PubMed ID: 30001207 [TBL] [Abstract][Full Text] [Related]
31. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Li Y; Liu Y; Wang Z; Jiang Y Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611 [TBL] [Abstract][Full Text] [Related]
32. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590 [TBL] [Abstract][Full Text] [Related]
33. Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model. Wang H; Li Y; Ryder JW; Hole JT; Ebert PJ; Airey DC; Qian HR; Logsdon B; Fisher A; Ahmed Z; Murray TK; Cavallini A; Bose S; Eastwood BJ; Collier DA; Dage JL; Miller BB; Merchant KM; O'Neill MJ; Demattos RB Mol Neurodegener; 2018 Dec; 13(1):65. PubMed ID: 30558641 [TBL] [Abstract][Full Text] [Related]
34. TREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response. Jiang T; Zhang YD; Gao Q; Ou Z; Gong PY; Shi JQ; Wu L; Zhou JS Inflammation; 2018 Jun; 41(3):811-823. PubMed ID: 29362997 [TBL] [Abstract][Full Text] [Related]
35. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Maphis N; Xu G; Kokiko-Cochran ON; Jiang S; Cardona A; Ransohoff RM; Lamb BT; Bhaskar K Brain; 2015 Jun; 138(Pt 6):1738-55. PubMed ID: 25833819 [TBL] [Abstract][Full Text] [Related]
36. Dephosphorylated rather than hyperphosphorylated Tau triggers a pro-inflammatory profile in microglia through the p38 MAPK pathway. Perea JR; Ávila J; Bolós M Exp Neurol; 2018 Dec; 310():14-21. PubMed ID: 30138606 [TBL] [Abstract][Full Text] [Related]
37. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope. Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925 [TBL] [Abstract][Full Text] [Related]
39. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia. Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543 [TBL] [Abstract][Full Text] [Related]
40. Live Imaging of Pathological Tau Protein and Tau Antibodies in a Neuron-Like Cellular Model. Shamir DB; Deng Y; Sigurdsson EM Methods Mol Biol; 2018; 1779():371-379. PubMed ID: 29886544 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]